Suppliers and packagers for REZLIDHIA

REZLIDHIA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814	NDA	Rigel Pharmaceuticals, Inc.	71332-005-01	30 CAPSULE in 1 BOTTLE (71332-005-01)	2022-12-01

Suppliers for the Pharmaceutical Drug: Rezlidhia

Last updated: July 28, 2025

Introduction

Rezlidhia (idhifa) is a targeted therapy drug used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring mutations in the IDH2 gene. Developed by Celgene, now part of Bristol-Myers Squibb (BMS), Rezlidhia has garnered attention due to its precision medicine approach. As the pharmaceutical landscape evolves, understanding the supplier ecosystem for Rezlidhia becomes crucial for stakeholders, including healthcare providers, pharmaceutical distributors, and investors.

Manufacturers and Production Ecosystem

Active Pharmaceutical Ingredient (API) Suppliers

The foundation of Rezlidhia’s supply chain resides in its active pharmaceutical ingredient (API), Idhifa (idhifa). The API manufacturing process is complex, involving specialized chemical synthesis and stringent quality controls. While Bristol-Myers Squibb (BMS) develops and controls the formulation and distribution of Rezlidhia, the supply of the API often involves multiple suppliers, sometimes across different regions, to meet global demand.

Currently, BMS has not publicly disclosed specific API manufacturing partners. However, industry norms suggest that such APIs are produced by highly specialized contract manufacturing organizations (CMOs). Notable global API manufacturers that serve the oncology segment include:

• Laurus Labs (India)
  Known for robust API production for oncology drugs, Laurus Labs supplies APIs to major pharmaceutical firms globally.

• Siegfried Holding AG (Switzerland)
  Specializes in complex chemical synthesis for APIs, including oncology compounds.

• Hetero Labs (India)
  Provides APIs and intermediates for targeted therapies.

Given the complexity and regulatory scrutiny of oncology APIs, it is plausible that BMS engages with one or multiple CMOs within these regions to ensure quality, regulatory compliance, and supply chain resilience.

Formulation and Finished Drug Product Suppliers

The final formulation and packaging of Rezlidhia are handled by BMS’s internal manufacturing facilities or contracted third-party pharmaceutical CDMOs. These manufacturing partners are responsible for:

• Blending and formulation
• Packaging at various dosage strengths
• Labeling and distribution logistics

In recent years, major pharma firms increasingly rely on CMOs such as Patheon (Thermo Fisher Scientific), Catalent, and Recipharm for formulation and finished goods production, owing to their extensive global networks and compliance capabilities.

Distribution and Supply Chain Partners

Global Distribution Networks

Rezlidhia’s distribution is managed by BMS’s extensive supply chain infrastructure, which leverages global logistics providers to distribute the medication worldwide. These include:

• DHL Supply Chain
• FedEx
• UPS Healthcare

Such logistics partners ensure temperature-sensitive transport, regulatory compliance, and efficient delivery across continents.

Regional and Local Distributors

In different markets, Rezlidhia is supplied via regional distributors or direct hospital supply channels, depending on local regulatory frameworks and market access strategies. Notable regional distributors include:

• Doctor’s Office Pharmacy chains
• Hospital networks
• Pharmacist networks

These entities often collaborate with commercial pharmacists and healthcare providers to ensure drug availability for eligible AML patients.

Regulatory and Quality Considerations

Given the targeted nature and potency of Rezlidhia, suppliers undergo rigorous regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national authorities. Approval of APIs and finished drug products involves comprehensive documentation on manufacturing processes, quality controls, and stability data.

BMS maintains rigorous supplier qualification programs, auditing manufacturing sites regularly to comply with Good Manufacturing Practice (GMP) standards, which emphasizes that the selection of suppliers is both strategic and meticulous.

Emerging Trends and Supply Chain Risks

The COVID-19 pandemic underscored vulnerabilities in pharmaceutical supply chains, especially for complex oncology drugs like Rezlidhia. Potential risks include:

• API supply shortages due to geopolitical tensions or manufacturing disruptions.
• Regulatory delays affecting manufacturing approvals.
• Regional supply constraints caused by logistical bottlenecks.

To mitigate these risks, BMS and other pharma manufacturers are diversifying their supplier base and investing in local or regional API production capacities.

Conclusion

While explicit supplier details for Rezlidhia remain proprietary and undisclosed publicly, the industry consensus indicates that API sourcing likely involves specialized CMOs across India, Switzerland, and other regions with expertise in oncology APIs. Finished drug formulation and distribution rely on partnerships with global CDMOs and logistics providers. Overall, the supply chain is characterized by its complexity, regulatory rigor, and ongoing adaptation to geopolitical and logistic challenges.

---

Key Takeaways

• Rezlidhia’s primary API is produced by specialized CMOs, likely in India or Switzerland, with BMS overseeing quality compliance.
• The formulation and packaging process is managed internally or through trusted contract manufacturers, leveraging global CDMO networks such as Patheon or Catalent.
• Distribution relies on leading logistics providers ensuring temperature-controlled transportation and regulatory adherence.
• Supply chain risks include geopolitical issues, manufacturing disruptions, and logistical bottlenecks, prompting strategic diversification.
• Transparency into specific suppliers remains limited due to proprietary confidentiality, emphasizing the importance for stakeholders to monitor industry trends and supplier audits.

---

FAQs

1. Who are the main manufacturing partners for Rezlidhia?
The specific partners are undisclosed; however, API production is presumed to be handled by highly specialized CMOs in regions like India or Switzerland, with formulation and distribution managed by Bristol-Myers Squibb’s supply chain network.

2. How does Bristol-Myers Squibb ensure the quality of Rezlidhia’s API?
BMS conducts rigorous supplier qualification and ongoing audits aligned with GMP standards, ensuring consistent quality, safety, and efficacy across global markets.

3. Are there risks associated with Rezlidhia’s supply chain?
Yes. Risks include geopolitical tensions affecting API sourcing, manufacturing disruptions, and logistical challenges, especially highlighted during the COVID-19 pandemic.

4. How is Rezlidhia distributed in international markets?
Distribution is managed via global logistics providers and regional pharmacy or hospital networks, ensuring timely access for eligible AML patients worldwide.

5. Will new suppliers emerge for Rezlidhia in the future?
Potentially. To mitigate supply risks, BMS may diversify or expand its supplier base, especially in light of regional capacity building and geopolitical considerations.

---

Sources

1. Bristol-Myers Squibb. (2022). Rezlidhia (idhifa) prescribing information.
2. Industry reports on API manufacturing and supply chain strategies in oncology.
3. Contract manufacturing organization profiles (e.g., Patheon, Catalent).
4. Logistics providers’ official documentation and global distribution standards.
5. Regulatory filings and disclosures related to Bristol-Myers Squibb and Rezlidhia.